Loading...
Anacetrapib is a new drug that raises HDL levels and reduces LDL levels by inhibiting the cholesteryl ester transfer protein (CETP). Another CETP inhibitor, torcetrapib, was withdrawn from development when it was found to increase rates of cardiovascular outcomes and death (JW Cardiol Nov 5 2007). Investigators have now conducted an international, manufacturer-funded, randomized, double-blind, placebo-controlled trial of anacetrapib in 1623 patients (mean age, 63) with or at high risk for coronary disease (55% and 45%, respectively).
By week 24, the mean LDL level had decreased significantly more in anacetrapib patients (from 81 mg/dL to 45 mg/dL) than in placebo patients (from 82 mg/dL to 77 mg/dL). The mean HDL level had increased signific…